| Completed | Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell NCT03520842 | Stanford University | Phase 2 |
| Withdrawn | Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads NCT03023904 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Withdrawn | Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer NCT03121417 | Emory University | Phase 2 |
| Unknown | Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That C NCT03048500 | Northwestern University | Phase 2 |
| Completed | Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer NCT02947386 | Roswell Park Cancer Institute | Phase 1 |
| Terminated | Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung NCT02846792 | University of Washington | Phase 1 / Phase 2 |
| Active Not Recruiting | Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-sm NCT03137771 | NRG Oncology | Phase 2 |
| Terminated | Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations NCT02949843 | Wake Forest University Health Sciences | Phase 2 |
| Completed | Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 NCT03049618 | University of Southern California | Phase 2 |
| Completed | TG4010 and Nivolumab in Patients With Lung Cancer NCT02823990 | Megan Daly, MD | Phase 2 |
| Completed | Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurre NCT02581943 | Wake Forest University Health Sciences | Phase 2 |
| Withdrawn | Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer NCT02451865 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Completed | Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomog NCT02819024 | Barbara Ann Karmanos Cancer Institute | N/A |
| Terminated | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Pro NCT02650635 | Mayo Clinic | Phase 1 |
| Terminated | MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer NCT02400814 | Megan Daly, MD | Phase 1 |
| Terminated | Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Remove NCT02566421 | Wake Forest University Health Sciences | N/A |
| Completed | Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib NCT02364609 | Jonathan Riess | Phase 1 |
| Active Not Recruiting | Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or NCT02495896 | University of Southern California | Phase 1 |
| Withdrawn | Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors NCT01971489 | Roswell Park Cancer Institute | Phase 1 |
| Terminated | Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma NCT02408016 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recu NCT02438722 | SWOG Cancer Research Network | Phase 2 / Phase 3 |
| Completed | Azacitidine in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer NCT02009436 | Albert Einstein College of Medicine | Phase 1 |
| Completed | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Ca NCT02206334 | NRG Oncology | Phase 1 |
| Completed | Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III NCT02186847 | NRG Oncology | Phase 2 |
| Terminated | Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surg NCT02134886 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Ce NCT01737502 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Photodynamic Therapy During Surgery in Treating Patients With Non-small Cell Lung Cancer That Can Be Removed b NCT01854684 | Roswell Park Cancer Institute | Phase 1 |
| Completed | PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stag NCT02073968 | Albert Einstein College of Medicine | Phase 2 |
| Completed | Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non- NCT01866410 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer NCT01935947 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Can NCT01727076 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced N NCT01620190 | University of Washington | Phase 2 |
| Terminated | Yoga in Improving Quality of Life in Patients With Non-small Cell Lung Cancer Undergoing Treatment NCT02895503 | Virginia Commonwealth University | N/A |
| Completed | MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Prog NCT01294306 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Canc NCT01193881 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors NCT01131234 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Rec NCT00955305 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NCT00963807 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-s NCT00738881 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small NCT00698815 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer NCT00602797 | University of Nebraska | Phase 2 |
| Completed | Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer NCT00387465 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurre NCT00950365 | Albert Einstein College of Medicine | Phase 2 |
| Terminated | Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients NCT00096265 | National Cancer Institute (NCI) | Phase 3 |